A Randomized, Double-blind,Phase Ⅲ Study of Liposome Doxorubicin in Desmoid Tumor
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
The aim of this study was to evaluate the efficacy and safety of liposomal doxorubicin in the
treatment of desmoid tumors. Unless the subject withdraws from the trial voluntarily, or the
researcher considers that the subject is not suitable for further trial, each subject will be
treated until the disease progresses or the toxic and side effects caused by the drug are
intolerable, and then enter the survival follow-up period